Dr. John Cush RheumNow
1 year 8 months ago
Treat-to-Target Improves Fertility in Women with RA
https://t.co/q9IMI5UHGO https://t.co/uhqaRXeBRX
Dr. John Cush RheumNow
1 year 8 months ago
JAMA FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar
- Dx often delayed 6-8 yrs
- Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/MWpznXqPzq https://t.co/46BkH4x9eE
Dr. John Cush RheumNow
1 year 8 months ago
Fibroblastic Rheumatism - JAMA Case: 50yoM w/ 3 yr hx of periarticular nodules, symmetric polyarthralgia at B/L PIPs. These were painful with manipulation or minor trauma. Labs negative. https://t.co/FeLH1GIHr9 https://t.co/Pj1FRHj25u
Dr. John Cush RheumNow
1 year 8 months ago
Biologic Monotherapy vs Combination with cDMARDs in PsA
https://t.co/MfqyD6hyOK https://t.co/fRJjOaJ9aT https://t.co/z8gutP79Ub
Dr. John Cush RheumNow
1 year 8 months ago
ICYMI: Shifting Trends in Initial RA Treatment Approaches
A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for RA over two decades in the US.
https://t.co/XlMXkuBBVN https://t.co/AHi3DG0aFV https://t.co/vNLF4Ft1GR
Axial spondyloarthritis (axSpA) affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their reproductive age. Two interesting abstracts about reproductive issues in axSpA will be presented during the poster sessions on Saturday, November 16, 2024.
Dr. John Cush RheumNow
1 year 8 months ago
DEA and the Department of Health and Human Services (HHS) has extended current telemedicine (TM) flexibilities through end 2025. MDs may Rx meds via TM (including narcotics) without in-office visits. https://t.co/C8lyB5feXg https://t.co/eSjYCnu02Y
Inebilizumab is an monoclonal antibody that targets and depletes CD19+ B cells and has been studied in adults with IgG4-related disease.
A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).
Dr. John Cush RheumNow
1 year 8 months ago
ACR24 IL-17 Topic Panel: Advancing Care with IL-17 Pathway Insights https://t.co/t9QQDYIrda
Dr. John Cush RheumNow
1 year 8 months ago
#ACR24: Rheumatology Roundup
https://t.co/0DMcpsAZce https://t.co/JvMnfAt3EP
Dr. John Cush RheumNow
1 year 8 months ago
Diagnostic Delays in PsA
Despite the remarkable expansion of the therapeutic armamentarium for psoriatic arthritis (PsA), the MONITOR-PsA study (abstract 1456) highlights a persistent and critical issue: delays in diagnosis.
https://t.co/83TeIpfutP https://t.co/85qo7F9IPa
